Gobalakichenane P, Lardennois C, Galène-Gromez S, Brossard V, Marpeau L, Verspyck E, Marret S
Service de pédiatrie néonatale et réanimation, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
Gynecol Obstet Fertil. 2008 Oct;36(10):984-90. doi: 10.1016/j.gyobfe.2008.07.012. Epub 2008 Sep 18.
To evaluate perinatal management and neurological outcome in a group of infants born with Rhesus fetomaternal allo-immunization.
Between 1 January and 31 December 2005, all newborns admitted to neonatal unit of Rouen tertiary centre for Rhesus hemolytic disease were included in a retrospective study and divided in two groups. The newborns who were treated with intrauterine transfusion are in the group 1 and those who needed only postnatal treatment in the group 2. In each case, were considered antenatal management (ultrasonographic data, middle cerebral artery peak systolic velocity, intrauterine transfusion), postnatal treatment (phototherapy, exchange transfusion, transfusion requirements) and neurological outcome.
Among 42 cases of Rhesus allo-immunization observed in six years, 28 newborns (67%) were admitted for neonatal cares. No case of fetal hydrops was noted. But 16/28 (57%) were preterm with a median term of 35 weeks gestation (32-36 weeks). In group 1 of six infants who had received intrauterine transfusion (IUT), only one (17%) needed postnatal exchange transfusion, and all six received one to three blood transfusions after their birth. In group 2 of 22 infants who did not receive IUT, 6/22 (27%) needed postnatal exchange and 18/22 (82%) of them received one to four blood transfusions. Phototherapy duration and albumin requirements were similar in both groups. Three deaths occurred, one due to necrotizing enterocolitis and the other two later on due to sudden infant death and fulminant meningococcemia. Neurological outcome of the remaining 25 children was normal.
Rhesus alloimmunization remain a situation at risk. Neonatal clinical presentation is less severe than previously described due to improvement in antenatal management. Infants required less postnatal exchange transfusion when they received intrauterine transfusion but more frequent blood transfusions.
评估一组患有恒河猴母胎血型不合免疫的婴儿的围产期管理及神经学结局。
在2005年1月1日至12月31日期间,鲁昂三级中心新生儿病房收治的所有因恒河猴溶血病入院的新生儿被纳入一项回顾性研究,并分为两组。接受宫内输血治疗的新生儿为第1组,仅需产后治疗的新生儿为第2组。每种情况均考虑产前管理(超声数据、大脑中动脉收缩期峰值流速、宫内输血)、产后治疗(光疗、换血疗法、输血需求)及神经学结局。
在六年内观察到的42例恒河猴血型不合免疫病例中,28例新生儿(67%)因新生儿护理入院。未发现胎儿水肿病例。但16/28(57%)为早产儿,中位孕周为35周(32 - 36周)。在接受宫内输血(IUT)的第1组的6例婴儿中,只有1例(17%)需要产后换血,且所有6例出生后均接受了1至3次输血。在未接受IUT的第2组的22例婴儿中,6/22(27%)需要产后换血,其中18/22(82%)接受了1至4次输血。两组的光疗持续时间和白蛋白需求量相似。发生了3例死亡,1例死于坏死性小肠结肠炎,另外2例后来分别死于婴儿猝死和暴发性脑膜炎球菌血症。其余25名儿童的神经学结局正常。
恒河猴血型不合免疫仍然是一种有风险的情况。由于产前管理的改善,新生儿临床表现不如先前描述的严重。接受宫内输血的婴儿产后换血需求较少,但输血更频繁。